Strata Oncology
Strata Oncology, based in Ann Arbor, Michigan, specializes in molecular profiling for advanced cancer treatment, offering comprehensive genomic profiling and proprietary biomarkers to guide immunotherapy.
Services
Strata Oncology offers a range of services aimed at improving cancer treatment through advanced molecular profiling. The Strata Select test provides treatment selection guidance for patients with advanced cancer, focusing on immunotherapy and other therapeutic options. Other services include comprehensive genomic profiling, which analyzes DNA and RNA across 437 genes, and predictive biomarker development like the Immunotherapy Response Score (IRS) for determining the effectiveness of anti-PD-1/PD-L1 immunotherapies. The company also runs the Strata PATH trial, which evaluates FDA-approved cancer therapies in novel, biomarker-guided patient populations.
Products
The primary product from Strata Oncology is the Strata Select molecular profiling test. This test offers treatment selection guidance for patients with advanced cancer by analyzing DNA and RNA across 437 genes. The key feature of this service is its focus on immunotherapy, although it extends beyond to other treatment options. Strata Oncology also developed the Immunotherapy Response Score (IRS), a proprietary biomarker that helps predict a patient’s response to anti-PD-1/PD-L1 immunotherapies. Through these products, the company aims to provide more targeted and effective treatment options for cancer patients.
Clinical Trials
Strata Oncology is involved in several pivotal clinical trials to advance cancer treatment. The Strata PATH trial is a pan-tumor therapeutic trial that evaluates FDA-approved cancer therapies in new, biomarker-guided patient populations. Another major initiative is the Strata Trial, a large-scale observational trial that assesses the clinical benefits of comprehensive genomic profiling for patients with advanced cancer. These clinical trials aim to validate and expand the use of molecular profiling in precision medicine, ultimately leading to more personalized and effective treatment options for cancer patients.
Headquarters
Strata Oncology is headquartered in Ann Arbor, Michigan. The company’s centralized location in this thriving hub of medical and scientific research allows it to collaborate closely with healthcare providers, researchers, and academic institutions. The headquarters functions as the primary center for research and development, coordination of clinical trials, and overall administration of its comprehensive cancer profiling services.